Cognition Therapeutics Reports 2025 Year-End Financial Results and Clinical Progress on Zervimesine

COGNITION THERAPEUTICS INC

Cash and equivalents $37.0M, net loss $23.5M for 2025 versus $34.0M net loss in 2024.
Completed enrollment in Phase 2 START trial in early Alzheimer's; topline results expected in 2027.
FDA Division of Psychiatry meeting anticipated by mid-2026 to discuss registrational plan for zervimesine in DLB psychosis.
Launched expanded access program for DLB patients following a philanthropic donation.
Appointed Dr. David Weinstein as VP of clinical development.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.

Period: the year ended December 31, 2025
Net income: $23.5 million, or $(0.32) per basic and diluted share
EPS: $(0.32) per basic and diluted share
Result: reported results

Exact text from the filing

$12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-26-034876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.